Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

Phagocytosis is a fundamental mechanism used by the body to resist pathogens and restore physiological homeostasis. Herein, to identify small molecules with anti-inflammatory properties via ...

A second drug candidate, BBO-10203, blocks the interaction between RAS and PI3K alpha, a family of enzymes involved in cellular growth and proliferation. While PI3K alpha inhibitors have reached ...